Lonza HLA-typed cells
Lonza now provides an expansive selection of high-resolution human leukocyte antigen (HLA)-typed primary cells spanning all major cell and tissue types. The ready-typed lots should eliminate the need for burdensome in-house sequencing processes and provide drug developers with a critical tool for the effective development of personalised therapies.
Nearly 50 different cell types are available from Lonza’s broad donor inventory, with detailed HLA data derived from gold-standard next-generation sequencing techniques. The offering builds on the company’s human primary cell capabilities to meet rapidly growing market demand for deeper and more comprehensive cell characterisation.
A person’s HLA type is a key determinant of the immune system’s response to foreign substances. HLA data is critical for preclinical exploration of cross-reactivities and off-target drug effects. HLA information is also needed for the development of engineered biotherapeutic T cell receptors and antibodies, patient stratification to optimise the clinical effectiveness of cancer therapies and the development of new cancer vaccines. As such, there is a rapidly growing market need for high-quality HLA-typed primary cells.
However, screening cell lots for HLA type can be lengthy and cumbersome to conduct in-house, and there is no guarantee that unscreened purchased lots will be the desired HLA type. Further, many vendors are only able to offer lots with lower-resolution HLA information obtained from serological typing methods, which can lead to incomplete HLA matching and poorer predictivity of in vitro models as a result. Being able to select lots with the desired high-resolution HLA data thus enables efficient preclinical development and boosts chances of drug development success.
Having previously offered HLA-typing services on a custom basis, Lonza is now providing high-resolution HLA information at no additional cost for a wide selection of its cell lots. With a diverse donor inventory that includes different age groups, genders and ethnicities, a broad range of donor cell lots with various HLA types is currently available, including HLA-A2*01.
Phone: 03 9550 0883
Tecan has launched the Crescendo cDNA Synthesis for qPCR system to provide increased sensitivity...
StarBright Blue 700, StarBright Violet 440 and StarBright Violet 610 are fluorescent...
Cayman Chemical's ferroptosis suppressor protein 1 (FSP1) and glutathione peroxidase 4 (GPX4)...